EpiBiome company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

epibiome.com

Founded Year

2013

Stage

Acquired | Acquired

Total Raised

$7.12M

Valuation

$0000 

About EpiBiome

EpiBiome is a precision microbiome engineering company based in South San Francisco with the mission of developing effective and sustainable FDA-approved therapies to combat infectious disease in humans and in agriculture without the use of antibiotics.

EpiBiome Headquarter Location

201 Gateway, Blvd. 2nd Floor

South San Francisco, California, 94080,

United States

650-825-1600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EpiBiome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiBiome is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

O

Omics

275 items

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest EpiBiome News

Illumina Accelerator Turns Five and Backs Five New Startups

Dec 5, 2019

Celebrates Continued Achievements by Inaugural Funding Cycle; Invests in Five New Companies for Tenth Cycle October 21, 2019 In October 2014, Illumina Accelerator announced the inaugural class of companies to join the world’s first business accelerator focused on creating an innovation ecosystem for the genomics industry. Illumina Accelerator’s goal is to build high-growth, venture-backable companies focused on advancing breakthrough applications in genomics to transform human health and beyond. Over the past half-decade, it has built a portfolio of 33 company graduates and helped them raise over $300 million in funding, collectively. Led by Amanda Cashin, Ph.D. and Illumina’s Chief Technology Officer Mostafa Ronaghi, Ph.D., Illumina Accelerator made its first investments in three startups who showed great potential to deliver innovative and breakthrough genomics applications. Fast forward five years and nine investment cycles, and the first three investments continue to thrive. Encoded Therapeutics is a biotech company developing precision gene therapies for severe genetic disorders by leveraging genomics-based technologies. The company’s lead program is focused on Dravet Syndrome, an intractable and severe form of genetic epilepsy. Encoded is developing a one-time, cell type selective gene therapy to address the underlying genetic mechanism of the disease. Since graduating from Illumina Accelerator, Encoded has raised over $158 million in funding from biotech investors to bring the company’s vision to patients. “The support we have received from our visionary group of investors, including Illumina Accelerator, is allowing Encoded to mature into a fully-integrated therapeutics company and establish itself as a leading innovator in gene therapy,” said Stephanie Tagliatela, Co-founder and Chief Scientific Officer, Encoded Therapeutics. Founded in 2013, Epibiome developed a high-throughput automated bacteriophage (“phage”) discovery platform integrating next-generation sequencing, bioinformatics, machine learning, and directed evolution technologies to rapidly create phage cocktails targeting pathogens with high unmet medical need. In July 2018, it was acquired by Locus Biosciences, a biotechnology company that develops CRISPR-engineered precision antibacterial products. Pairing EpiBiome’s phage isolation and characterization capability with Locus’s CRISPR-based synthetic biology platform and clinical development team, created a combined entity poised to develop therapeutics to treat antibiotic-resistant bacterial infections and microbiome-associated diseases, which have become major problems in health care. Earlier this year, Locus formed a collaboration with Janssen, worth approximately $818 million. “During our time at Illumina Accelerator, we worked to build a one-of-a-kind, high-throughput phage discovery platform, which has allowed us to create phage cocktails that can selectively remove a target bacterial species while leaving all other bacteria alone,” said Aeron Hammack, Ph.D., Co-founder, EpiBiome. Xcell Biosciences is a San Francisco-based life sciences company with a novel cell therapy development platform designed to significantly enhance the clinical performance of immune cell therapies. So far, the company has raised $16 million and has grown to a team of 15. Xcell’s core technology is an IP-protected cell manufacturing platform which benefits from novel and proprietary environmental control elements and a range of real-time sensor inputs. The platform enables enhancement of immune cell phenotype and function towards a defined target profile during clinical production. “When we started at Illumina Accelerator, we were at the beginning stages of our research with only a breadboard instrument and a narrow set of supporting data. We focused on culturing both tumor cells and immune cells within the tumor microenvironment and saw the tremendous value of the information contained within those cells for decision-making in the clinic,” said Brian Feth, Co-founder and Chief Executive Officer, Xcell Biosciences. Co-founder of Illumina Accelerator, Mostafa Ronaghi said, “Over the last five years, we’ve worked to build Illumina Accelerator’s best-in-class reputation with a network of smart and innovative companies, which began with our first class of genomics startups. This particular group set the bar high, and it’s exciting to see not only how far they’ve come but how far they’re still working to go.” The Tenth Funding Cycle Illumina Accelerator San Francisco Bay Area welcomes five promising companies to its tenth cycle of investments, providing each company with access to seed investment, business and scientific guidance, access to Illumina’s sequencing systems and reagents, and fully operational lab space for six months. The tenth cycle includes: 4Basecare Genomics Pte Ltd, a precision oncology company in India and Singapore, is developing genomics enabled personalized cancer diagnostics, data sets and treatment guidance solutions for cancer patients in Asia. Felix Biotechnology, Inc., a biotherapeutic company from the San Francisco Bay Area, is focused on accelerating the deployment of novel biotherapeutics targeting urgent microbial challenges in human health and beyond. Jenthera Therapeutics Inc., a gene editing therapeutics company from Montreal, Canada, is developing next-generation CRISPR therapeutics with its novel full spectrum editing system for precision gene alteration and disruption capabilities. Lassogen, Inc., a biotech company located in San Diego, CA, is developing a proprietary platform involving lasso peptides as a novel therapeutic modality to diagnose and treat disease. Stem Pharm, Inc., a tools company from Madison, WI, provides advanced biomaterials for cell and tissue manufacturing with applications in drug discovery, cell therapy and regenerative medicine. “With every cycle, we’ve seen another level of excellence in both the ideas and the ambition of these startups,” said Amanda Cashin, Co-Founder and Global Head of Illumina Accelerator. “With our recent global expansion to Cambridge, UK, we’re able to expand our geographical reach and create even more genomics-driven startups.” In July 2019, Illumina Accelerator announced its global expansion to Cambridge, UK , broadening its international reach offering a new site for entrepreneurs across Europe, Africa, the Middle East and beyond to build genomics driven startups and expand the innovation ecosystem. Through a single, global application process, Illumina Accelerator will select up to five companies in both the San Francisco Bay Area and Cambridge, UK to participate in two, six-month cycles per year. Applications for the eleventh cycle of Illumina Accelerator San Francisco Bay Area and the inaugural funding cycle of Illumina Accelerator Cambridge are due on November 1. To learn more and apply, please visit our  website .

  • When was EpiBiome founded?

    EpiBiome was founded in 2013.

  • Where is EpiBiome's headquarters?

    EpiBiome's headquarters is located at 201 Gateway, Blvd., South San Francisco.

  • What is EpiBiome's latest funding round?

    EpiBiome's latest funding round is Acquired.

  • How much did EpiBiome raise?

    EpiBiome raised a total of $7.12M.

  • Who are the investors of EpiBiome?

    Investors of EpiBiome include Locus Biosciences, Silicon Valley Bank, Illumina Accelerator, Viking Global Investors, CRCM Ventures and 6 more.

  • Who are EpiBiome's competitors?

    Competitors of EpiBiome include AgBiome and 2 more.

You May Also Like

B
Benson Hill Biosystems

Benson Hill Biosystems leverages cloud biology, comprised of cloud computing, big data analytics, and plant biology to enable companies of all sizes to improve crop genetics. CropOS is a cognitive engine that uses machine learning to continuously advance, enabling researchers to predict which seeds will produce a desired trait. The platform outputs can be deployed in crop plants by using a spectrum of approaches and tools, from breeding to genome editing to transgenics.

AgBiome Logo
AgBiome

AgBiome is a product-oriented biotechnology company focused on delivering early-stage research and discovery to the agriculture industry. AgBiome's first product is a biological that controls the predominant soil-borne diseases of greenhouse and major row crops. AgBiome is also applying genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance and yield.

Trace Genomics Logo
Trace Genomics

Trace Genomics develops molecular assay for soil and seed-borne pathogens which enables detection of pathogens and beneficial organisms simultaneously. The company's assay is based on genetic sequencing technology, enabling strain-specific identification. Trace Genomics uses artificial intelligence techniques used in fraud detection and data science to identify microbes and genetic mutations that cause or protect from disease, enabling insights into soil health and methods to increase crop quality, including yield and shelf life.

E
Enko Chem

Enko operates a digital discovery platform and pipeline of crop health molecules. The company offers a product pipeline of crop protection chemistries that target critical pests and weeds. Enko Chem serves clients operating in the agriculture sector. It was founded in 2017 and is based in Mystic, Connecticut.

Farmers Business Network Logo
Farmers Business Network

Farmers Business Network (FBN) allows farmers to anonymously share data about everything from seed performance to chemical pricing, harnessing the power of data science to help farmers make more informed decisions. FBN members receive comprehensive yield benchmarking, real world product performance analysis, and agronomic analytics based on real world data from the FBN community. The FBN Direct farm-commerce platform works with manufacturers to deliver substantially reduced input prices to members. FBN Direct's transparent pricing system has helped farmers realize savings of up to 50 percent on critical inputs.

A
Archer Daniels Midland Company

Archer Daniels Midland Company is an agricultural processor. The company takes crops and processes them to make food ingredients, animal feed ingredients, renewable fuels, and naturally derived alternatives to industrial chemicals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.